Call Start: 16:30 January 1, 0000 5:23 PM ET

Cue Biopharma, Inc. (NASDAQ:CUE)

Q3 2022 Earnings Conference Call

November 14, 2022 16:30 ET

Company Participants

Dan Passeri - Chief Executive Officer

Anish Suri - President & Chief Scientific Officer

Ken Pienta - Acting Chief Medical Officer

Matteo Levisetti - Senior Vice President of Clinical Development

Kerri Millar - Chief Financial Officer

Conference Call Participants

Reni Benjamin - JMP Securities

Stephen Willey - Stifel

Mark Breidenbach - Oppenheimer

Ted Tenthoff - Piper Sandler

Operator

Greetings, and welcome to the Cue Biopharma Update Call. A question-and-answer session will follow the presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you, sir. Please begin.

Dan Passeri

Thank you, and good afternoon, everyone. Before I begin, I'd like to remind everyone that you have the slides in front of you that you need to operate manually, and we will notify you what slide we are on. Joining me on today's call is Dr. Anish Suri, our President and CFO; Dr. Ken Pienta, our Acting Chief Medical Officer; and Dr. Matte Levisetti, our Senior Vice President of Clinical Development; as well as Kerri Millar, our Chief Financial Officer. This conference is being recorded and will be available on our website for the next 30 days.

As a reminder, and as shown here on Slide number 2, this presentation and overview may contain some forward-looking statements, and any forward-looking statements made during this call represents the company's views only as of today, November 14, 2022. Our agenda for today's call is shown on the next slide, Slide 3.

I'll begin by providing an overview of our competitive and strategic positioning based upon data from both our monotherapy trial of CUE-101 as well as the data just recently reported at SITC from our CUE-101 and KEYTRUDA combination trial. Mateo and -- can will provide this -- a review of this data in further detail momentarily. But first, I want to provide context pertaining to the underlying implications and importance of the data sets observed to date. As you are aware, the ultimate promise of immunotherapy is to enable the intrinsic potential of a patient's immune system to recognize and kill cancer. We believe through our representative data generated from both our monotherapy trial and combination trials of CUE-101, our IL-2-based Q100 series is now well positioned to become a first-in-class selective T cell engager and best-in-class IL-2 for cancer immunotherapy, as shown here on Slide number 4.